Teva Pharmaceutical Industries (TEVA) Cash from Financing Activities (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Cash from Financing Activities for 18 consecutive years, with -$1.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Financing Activities fell 116.67% year-over-year to -$1.0 million; the trailing twelve-month figure through Jun 2026 stood at -$401.0 million (up 83.37% YoY), and the FY2025 full-year result was -$2.2 billion, down 20.1% from the prior year.
• Cash from Financing Activities retreated to -$1.0 million in Q2 2026 per TEVA's latest filing, from $13.0 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $40.0 million in Q4 2025 and bottomed at -$1.7 billion in Q1 2025.
• Historically, Cash from Financing Activities has averaged -$431.1 million across 5 years, with a median of -$439.0 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities plunged 35400.0% in 2023, then jumped 105.93% in 2025.
• Over 5 years, Cash from Financing Activities stood at -$711.0 million in 2022, then gained by 18.99% to -$576.0 million in 2023, then decreased by 17.01% to -$674.0 million in 2024, then jumped by 105.93% to $40.0 million in 2025, then sank by 102.5% to -$1.0 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$1.0 million, $13.0 million, and $40.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.